GSK receives FDA approval for Lamictal XR to treat partial seizures
Links shared publicly online about this topic.
- 338total visits
GSK receives FDA approval for Lamictal XR to treat partial seizures
GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.
View full resource at news-medical.net
Tags: Meningitis, Seizure Medication, FDA, Lamictal, GlaxoSmithKline, Epilepsy Medication, News
Most Recently Shared on April 26, 2011 at 5:53 am By:
Meningitis News: GSK receives FDA approval for Lamictal XR to treat partial seizures: GlaxoSmithKline announced ... http://bit.ly/gqHi0M
FDA Approves Lamictal®XR™ (Lamotrigine) For Conversion To Monotherapy For Treatment Of Partial Seizures In Appropriate Patients
medicalnewstoday.com — “GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved Lamictal® XR™ (lamotrigine) Extended-Release Tablets for conversion to monotherapy in patien” View full resource at medicalnewstoday.com
Most Recently Shared on April 27, 2011 at 8:05 am By:
MNT Clinical Trials Health News
FDA Approves Lamictal®XR™ (Lamotrigine) For Conversion To Monotherapy For Treatment Of Partial Seizures In A... http://mnt.to/3V4D
Advertisement
